Differences in the transactivation domains of p53 family members: a computational study

The N terminal transactivation domain of p53 is regulated by ligases and coactivator proteins. The functional conformation of this region appears to be an alpha helix which is necessary for its appropriate interactions with several proteins including MDM2 and p300. Folding simulation studies have been carried out to examine the propensity and stability of this region and are used to understand the differences between the family members with the ease of helix formation following the order p53 > p73 > p63. It is clear that hydrophobic clusters control the kinetics of helix formation, while electrostatic interactions control the thermodynamic stability of the helix. Differences in these interactions between the family members may partially account for the differential binding to, and regulation by, MDM2 (and MDMX). Phosphorylations of the peptides further modulate the stability of the helix and control associations with partner proteins.

[1]  L. M. Espinoza-Fonseca.  Leucine‐rich hydrophobic clusters promote folding of the N‐terminus of the intrinsically disordered transactivation domain of p53 , 2009, FEBS letters.

[2]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[3]  J. Trujillo-Ferrara,et al.  Transient stability of the helical pattern of region F19-L22 of the N-terminal domain of p53: a molecular dynamics simulation study. , 2006, Biochemical and biophysical research communications.

[4]  Tim Crook,et al.  Functional regulation of p73 and p63: development and cancer. , 2003, Trends in biochemical sciences.

[5]  H. Berendsen,et al.  ALGORITHMS FOR MACROMOLECULAR DYNAMICS AND CONSTRAINT DYNAMICS , 1977 .

[6]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[7]  Johannes Buchner,et al.  p53 contains large unstructured regions in its native state. , 2002, Journal of molecular biology.

[8]  H. Carlson,et al.  Computational studies and peptidomimetic design for the human p53–MDM2 complex , 2004, Proteins.

[9]  J. Pietenpol,et al.  p63 and epithelial biology. , 2006, Experimental cell research.

[10]  David P Lane,et al.  Molecular simulations of protein dynamics: new windows on mechanisms in biology , 2008, EMBO reports.

[11]  Ken A Dill,et al.  A test on peptide stability of AMBER force fields with implicit solvation. , 2008, The journal of physical chemistry. B.

[12]  D. Case,et al.  Exploring protein native states and large‐scale conformational changes with a modified generalized born model , 2004, Proteins.

[13]  N. Little,et al.  Hdmx and Mdm2 can repress transcription activation by p53 but not by p63 , 2001, Oncogene.

[14]  A. Yang,et al.  Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.

[15]  Peter S. Kutchukian,et al.  All-atom model for stabilization of alpha-helical structure in peptides by hydrocarbon staples. , 2009, Journal of the American Chemical Society.

[16]  L. Vassilev,et al.  Targeting protein–protein interactions for cancer therapy , 2005, Journal of Molecular Medicine.

[17]  Neal J. Zondlo,et al.  Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2-binding motif of p53. , 2006, Biochemistry.

[18]  Shubhra Ghosh Dastidar,et al.  Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. , 2008, Journal of the American Chemical Society.

[19]  P. Secchiero,et al.  Combined treatment of CpG‐oligodeoxynucleotide with Nutlin‐3 induces strong immune stimulation coupled to cytotoxicity in B‐chronic lymphocytic leukemic (B‐CLL) cells , 2008, Journal of leukocyte biology.

[20]  G Melino,et al.  The p53/p63/p73 family of transcription factors: overlapping and distinct functions. , 2000, Journal of cell science.

[21]  F. McKeon,et al.  Mutations in the p53 homolog p63: allele-specific developmental syndromes in humans. , 2002, Trends in molecular medicine.

[22]  M. Barton,et al.  Family Members p53 and p73 Act Together in Chromatin Modification and Direct Repression of α-Fetoprotein Transcription* , 2005, Journal of Biological Chemistry.

[23]  G. Wahl,et al.  MDM2 and MDM4: p53 regulators as targets in anticancer therapy. , 2007, The international journal of biochemistry & cell biology.

[24]  D. Lane,et al.  Identification of novel mdm2 binding peptides by phage display. , 1996, Oncogene.

[25]  S. Korsmeyer,et al.  Reactivation of the p53 Tumor Suppressor Pathway by a Stapled p53 Peptide , 2007 .

[26]  K Schulten,et al.  VMD: visual molecular dynamics. , 1996, Journal of molecular graphics.

[27]  Chong Li,et al.  Turning a scorpion toxin into an antitumor miniprotein. , 2008, Journal of the American Chemical Society.

[28]  C. Harris,et al.  p53 tumor suppressor gene: from the basic research laboratory to the clinic--an abridged historical perspective. , 1996, Carcinogenesis.

[29]  F. McKeon,et al.  DNA-Binding and Transactivation Activities Are Essential for TAp63 Protein Degradation , 2005, Molecular and Cellular Biology.

[30]  H. Jane Dyson,et al.  Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2 , 2009, Proceedings of the National Academy of Sciences.

[31]  D. Livingston,et al.  Binding and modulation of p53 by p300/CBP coactivators , 1997, Nature.

[32]  Kyou-Hoon Han,et al.  Local Structural Elements in the Mostly Unstructured Transcriptional Activation Domain of Human p53* , 2000, The Journal of Biological Chemistry.

[33]  G. Blandino,et al.  p73 Is Regulated by Phosphorylation at the G2/M Transition* , 2003, Journal of Biological Chemistry.

[34]  W. Richardson,et al.  Roles for p53 and p73 during oligodendrocyte development , 2004, Development.

[35]  K. Gardner,et al.  Recruitment of p300/CBP in p53-Dependent Signal Pathways , 1997, Cell.

[36]  Matthias Dobbelstein,et al.  p73 and p63: Why Do We Still Need Them? , 2004, Cell cycle.

[37]  N. Perkins,et al.  DNA-dependent Acetylation of p53 by the Transcription Coactivator p300* , 2003, The Journal of Biological Chemistry.

[38]  Michael Feig,et al.  MMTSB Tool Set: enhanced sampling and multiscale modeling methods for applications in structural biology. , 2004, Journal of molecular graphics & modelling.

[39]  D. Roop,et al.  p63 and epithelial appendage development. , 2004, Differentiation; research in biological diversity.

[40]  H. Vogel,et al.  p63 is a p53 homologue required for limb and epidermal morphogenesis , 1999, Nature.

[41]  Deepak Srinivasan,et al.  Modulation of the p53-MDM2 Interaction by Phosphorylation of Thr18: A Computational Study , 2007, Cell cycle.

[42]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[43]  A. Fersht,et al.  Structural biology of the tumor suppressor p53. , 2008, Annual review of biochemistry.

[44]  D. Lane,et al.  Design of a novel MDM2 binding peptide based on the p53 family , 2009, Cell cycle.

[45]  Y. Haupt.  p53 Regulation: a family affair. , 2004, Cell cycle.

[46]  W. Gu,et al.  Leading Edge Review Modes of p 53 Regulation , 2009 .

[47]  Oliver Zerbe,et al.  Structure–Activity Studies in a Family of β‐Hairpin Protein Epitope Mimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction , 2006 .

[48]  Chong Li,et al.  Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX , 2009, Proceedings of the National Academy of Sciences.

[49]  T. Cross,et al.  Water: foldase activity in catalyzing polypeptide conformational rearrangements. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  G. Melino,et al.  TAp63α induces apoptosis by activating signaling via death receptors and mitochondria , 2005, The EMBO journal.

[51]  John A. Robinson.  Beta-hairpin peptidomimetics: design, structures and biological activities. , 2008, Accounts of chemical research.

[52]  The electrostatic surface of MDM2 modulates the specificity of its interaction with phosphorylated and unphosphorylated p53 peptides , 2008, Cell cycle.

[53]  Xiaoqi Wang,et al.  MDM2 and MDMX can interact differently with ARF and members of the p53 family , 2001, FEBS letters.

[54]  Sarah W. Burge,et al.  Molecular basis of the interactions between the p73 N terminus and p300: Effects on transactivation and modulation by phosphorylation , 2009, Proceedings of the National Academy of Sciences.

[55]  Christopher P. Crum,et al.  p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development , 1999, Nature.

[56]  A. Valent,et al.  P73 functionally replaces p53 in Adriamycin‐treated, p53‐deficient breast cancer cells , 2005, International journal of cancer.

[57]  T. Parisi,et al.  The Human MDM2 Oncoprotein Increases the Transcriptional Activity and the Protein Level of the p53 Homolog p63* , 2002, The Journal of Biological Chemistry.

[58]  J. Momand,et al.  Solution conformation of an essential region of the p53 transactivation domain. , 1997, Folding & design.

[59]  A. Fersht,et al.  Molecular mechanism of the interaction between MDM2 and p53. , 2002, Journal of molecular biology.

[60]  John A. Robinson,et al.  Structure-activity studies in a family of beta-hairpin protein epitope mimetic inhibitors of the p53-HDM2 protein-protein interaction. , 2006, Chembiochem : a European journal of chemical biology.

[61]  W. El-Deiry,et al.  Regulation of p53 downstream genes. , 1998, Seminars in cancer biology.

[62]  R. Tjian,et al.  p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. , 1995, Science.

[63]  Wei Gu,et al.  Modes of p53 Regulation , 2009, Cell.

[64]  Kristian Helin,et al.  Amplification of Mdmx (or Mdm4) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity , 2004, Molecular and Cellular Biology.

[65]  John A. Robinson,et al.  1 Thermodynamic and Computational Studies on the Binding of p 53-Derived Peptides and Peptidomimetic Inhibitors to HDM 2 , 2009 .

[66]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[67]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.